Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 MorphoSys U.S. Inc., a fully owned subsidiary
UCART22 is currently the most advanced allogeneic CAR T-cell product in development for relapsed or refractory B-cell acute lymphoblastic leukemia The BALLI-01 study is actively enrolling patients. | April 11, 2023
While the Oklahoma Turnpike Authority hopes the state Supreme Court will validate the issuance of billions in bonds for new projects, two local attorneys said Friday the agency will likely
By Colin Kellaher Caribou Biosciences Inc. on Tuesday said the U.S. Food and Drug Administration granted fast-track designation to CB-011, in development for relapsed or refractory multiple. | April 4, 2023
In Three-Year Follow-up in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, Tecartus Shows High Rates of Durable Response (CR+CRi 71%) and a Median Overall Survival of 26 Months